Roquefort Therapeutics

Our portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.

The highly complementary portfolio of best-in-class medicines is focused on the cancers that remain resistant to existing therapies and creates significant upside potential in high value and high growth oncology market.

Expert leadership team with proven track record in drug development, regulatory approvals and biotech transactions.

The team includes Nobel Laureate, Professor Sir Martin Evans and experienced biotechnology CEO, Ajan Reginald.

State of the art laboratory located in Stratford-upon-Avon includes a clean room, laminar flow cabinets and cryopreservation infrastructure required for pre-clinical development of innovative new medicines, particularly cell and gene therapies.

Network of partnerships with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy.

This distributed R&D model is highly scalable and cost effective.